Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 16Parkinson Disease 4, Autosomal Dominant Lewy Body 4Small Cell Lung Carcinoma 3Carcinoma 3Urothelial Cancer 2Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Endometrial Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Recurrence 1Ovarian Neoplasms 1Oligodendroglioma 1Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1Non Small Cell Lung Cancer NSCLC 1Neurocytoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Metastatic Urothelial Cancer 1Mesothelioma 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1

Interventions

Gemcitabine 2Cisplatin 2Carboplatin 2pembrolizumab 1erdafitinib 1enfortumab vedotin 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Urothelial Cancer × Carboplatin × Clear all
NCT04223856 2026-05-29

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting
886 enrolled 12 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT03036098 2026-03-06

CheckMate901

Bristol-Myers Squibb

Phase 3 Active not recruiting
1,314 enrolled 23 charts 1 FDA
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡